NSE · LINCOLN
Lincoln Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹177 Cr with net profit ₹36 Cr — a 20.44% net margin, versus 6.21% the period before.
Shareholding
As of 2026-06-30
- Promoter49.78%
- Public45.36%
- FII4.6%
- DII0.27%
29,396 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.75× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #17 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,83,052 Cr | 82.04 | 21.82 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹46,642 Cr | 40.71 | 4.51 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,847 Cr | 38.64 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,245 Cr | 101.48 | 22.65 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹19,634 Cr | 29.51 | 5.83 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,151 Cr | 63.83 | 7 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,060 Cr | 27.49 | 4.64 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,340 Cr | 27.76 | 4.74 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,236 Cr | 52.55 | 6.06 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,341 Cr | 50.18 | 6.76 | 12.36% | 18.59% |
| Lincoln Pharmaceuticals Ltd.(this company) | ₹1,183 Cr | 12.27 | 1.56 | 11.6% | 13.89% |
AI analysis
AI-generated · google/gemini-2.5-flashLincoln Pharmaceuticals Ltd. (LINCOLN) has a market capitalization of Rs 1196 Cr. The company reported annual revenue of Rs 645.71 Cr and an EPS of 41.11. Its book value per share is Rs 335.34. The promoter holding stands at 49.7757% as of June 2026.
Positives
- +The debt-to-equity ratio is 0, indicating no debt.
- +The promoter pledge is 0%, meaning no shares are pledged by the promoters.
- +Return on Capital Employed (ROCE) at 15.1776% indicates efficient use of capital.
Negatives
- −Promoter holding decreased from an unspecified value prior to June 2026 to 49.7757% by June 2026.
- −Net profit in the latest quarter (Mar 2026) was Rs 11.63 Cr, the lowest in the last five reported quarters.
- −Revenue growth information is not available.
- −Dividend yield information is not available.
- −Profit margin information is not available.
Financial Performance
For the fiscal year ending March 2025, Lincoln Pharmaceuticals Ltd. reported total revenue of Rs 645.71 Cr and a net profit of Rs 82.3464 Cr. The earnings per share (EPS) for this period was Rs 41.11. In the most recent quarter (March 2026), revenue stood at Rs 187.28 Cr with a net profit of Rs 11.63 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 13%. Return on Capital Employed (ROCE) is 15.1776%. The P/E ratio is 13.42 based on an EPS of 41.11. The EBITDA for the fiscal year ending March 2025 was Rs 111.0714 Cr.
Balance Sheet
Lincoln Pharmaceuticals Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 335.34. Further details regarding assets and liabilities are not available in the provided data.
Ownership & Pledges
As of June 2026, the promoter holding in Lincoln Pharmaceuticals Ltd. is 49.7757%. The public shareholding is 45.3566%. There are no shares pledged by the promoters.
Regulatory & Surveillance
There is no information regarding any regulatory or surveillance actions for Lincoln Pharmaceuticals Ltd. in the provided data.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Lincoln Pharmaceuticals Ltd.share price & fundamentals